Collegium Pharmaceutical Inc (COLL) Expected to Announce Earnings of -$0.06 Per Share

Equities analysts expect that Collegium Pharmaceutical Inc (NASDAQ:COLL) will post earnings per share of ($0.06) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings. The highest EPS estimate is $0.08 and the lowest is ($0.21). Collegium Pharmaceutical reported earnings of ($0.54) per share in the same quarter last year, which would indicate a positive year over year growth rate of 88.9%. The firm is scheduled to report its next earnings results on Wednesday, March 6th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.75) per share for the current year, with EPS estimates ranging from ($0.96) to ($0.49). For the next year, analysts anticipate that the company will post earnings of $0.65 per share, with EPS estimates ranging from $0.12 to $1.20. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The business had revenue of $70.20 million during the quarter, compared to analysts’ expectations of $74.79 million. During the same quarter in the previous year, the company posted ($0.45) earnings per share. The company’s quarterly revenue was up 485.0% compared to the same quarter last year.

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald set a $35.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Friday, September 21st. BidaskClub upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday, October 4th. Janney Montgomery Scott set a $27.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Monday, August 6th. HC Wainwright reiterated a “buy” rating on shares of Collegium Pharmaceutical in a report on Monday, September 17th. Finally, Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, October 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $31.71.

Shares of NASDAQ COLL traded up $0.53 during midday trading on Friday, hitting $17.38. The company’s stock had a trading volume of 635,400 shares, compared to its average volume of 518,392. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.75 and a current ratio of 0.78. Collegium Pharmaceutical has a 12-month low of $13.70 and a 12-month high of $29.90. The company has a market cap of $570.19 million, a price-to-earnings ratio of -7.04 and a beta of 0.24.

In related news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $16.60, for a total value of $415,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 25.76% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Highland Capital Management LP grew its stake in Collegium Pharmaceutical by 67.8% in the second quarter. Highland Capital Management LP now owns 508,822 shares of the specialty pharmaceutical company’s stock worth $12,135,000 after purchasing an additional 205,600 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in Collegium Pharmaceutical by 23.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 29,539 shares of the specialty pharmaceutical company’s stock valued at $705,000 after acquiring an additional 5,640 shares in the last quarter. Granahan Investment Management Inc. MA boosted its position in Collegium Pharmaceutical by 192.3% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 127,460 shares of the specialty pharmaceutical company’s stock valued at $3,040,000 after acquiring an additional 83,860 shares in the last quarter. Millennium Management LLC boosted its position in Collegium Pharmaceutical by 1,171.8% during the 2nd quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock valued at $8,611,000 after acquiring an additional 332,647 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Collegium Pharmaceutical by 203.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 155,374 shares of the specialty pharmaceutical company’s stock valued at $3,706,000 after acquiring an additional 104,255 shares in the last quarter. 94.95% of the stock is currently owned by institutional investors.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Read More: Depreciation

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply